Antibody Information

General Information of This Antibody

Antibody ID	ANI0VWJKO
Antibody Name	Humanized anti-SLAMF2 SGN-CD48A mAb
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	CD48 antigen (CD48)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

SGN-CD48A [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT03379584	Clinical Status	Phase 1
Clinical Description	A phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	75.00%	Positive SLAMF2 expression (SLAMF2+++/++)
Method Description	SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Plasma cell myeloma	EJM cells		CVCL_2030
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	87.50%	Positive SLAMF2 expression (SLAMF2+++/++)
Method Description	SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 1.00 mg/kg.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Plasma cell myeloma	U-266 cells		CVCL_0015
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Positive SLAMF2 expression (SLAMF2+++/++)
Method Description	SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.00-11.00 ng/mL	High CD48 expresion (CD48+++/++; 1260 MSLN molecules/cell)
Method Description	Cytotoxic activity of SGN-CD48A was demonstrated in a panel of human MM cell lines in vitro.
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens

References

Ref 1	A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
Ref 2	SGN-CD48A: a Novel Humanized Anti-CD48 Antibody-Drug Conjugate for the Treatment of Multiple Myeloma. Blood. 2016 Dec 2;128(22):4470.